Igal Rosenstein

发表

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

A. Risedal, F. Piehl, E. Gilland, 2022, The Lancet Neurology.

CSF1R-Related Leukoencephalopathy Caused by CSF1R p.Arg777Trp and CSF1R p.Arg782Cys Mutations: A Report of Four Cases in Sweden

E. Englund, V. Karrenbauer, T. Granberg, 2021 .

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis

K. Blennow, H. Zetterberg, J. Lycke, 2022, Frontiers in Immunology.

Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real‐world investigation

K. Blennow, H. Zetterberg, J. Lycke, 2021, Journal of neurochemistry.

Four Swedish cases of CSF1R‐related leukoencephalopathy: Visualization of clinical phenotypes

E. Englund, T. Granberg, O. Andersen, 2021, Acta neurologica Scandinavica.

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis

K. Blennow, H. Zetterberg, J. Lycke, 2023, Frontiers in Immunology.

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study

K. Blennow, H. Zetterberg, J. Lycke, 2021, Multiple sclerosis.

Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis.

J. Borén, S. Cardell, E. Björnson, 2023, Multiple sclerosis and related disorders.

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis

K. Blennow, H. Zetterberg, J. Lycke, 2023, Journal of Neurology.